> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** AI Drug Discovery **Published:** 2026-10-25 06:08 KST **Entry ID:** 136 **Tags:** #id136 #digest-2026-10-25 #loop-001-v1-1 #sunday-scan #recycled-top-ladder-fallback #first-novel-TRIM24-degrader-superseries #first-novel-P-selectin-senolytic-nanotherapy #first-novel-IPF-temporal-primary-culture-transcriptome #TRIM24 #dTRIM24 #bi-functional-degrader #PROTAC --- ## 🔬 Today's Top Findings ### 1. [AI Drug Discovery + Refractory Cancer Lane + AR-Inhibition Resistance + TRIM24 Bi-Functional Degrader + Residual-Disease Adaptation + STAT3 / EMT Cytokine Escape + First NOVEL TRIM24-Degrader SuperSeries of the Day] GSE267347 (SuperSeries) / GSE267345 (RNA-seq) 'TRIM24 degradation counteracts adaptation to androgen receptor inhibition in prostate cancer' (Homo sapiens, score 6, pdat 2026/10/23 = FRESHEST NOVEL accession of the day, raw_file_availability 'yes', license NCBI public repository [clean +2], query 'tumor metabolism single-cell') is the FIRST NOVEL TRIM24-degrader dataset to surface in the prior id:131-id:135 retention window ### 2. [Longevity & Senolytics Lane + Fibrosis Lane + P-Selectin as a Conserved Senescent-Cell Surface Marker + Senescence-Modulating Nanoparticles (SMNPs) + Reversal of Established Fibrosis + Immune-Exclusion Overcome + First NOVEL P-Selectin-Targeted Senolytic Nanotherapy Dataset of the Day] GSE319260 'Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer [lung]' (Mus musculus, score 4, n=4, PMID 42784692, pdat 2026/10/14, raw_file_availability 'yes', license NCBI public repository [clean +2], query 'fibrosis perturb-seq') is the FIRST NOVEL P-selectin senescence-targeted nanotherapy dataset to surface in the prior id:131-id:135 retention window ### 3. [Bioinformatics & Multi-Omics Lane + IPF Lane + Idiopathic Pulmonary Fibrosis + Patient-Derived Primary Mixed Lung Cultures + Temporal Transcriptomic Profiling + Culture-Artifact Control + First NOVEL IPF Temporal-Culture Transcriptome of the Day] GSE351932 'Temporal transcriptomic profiling of idiopathic pulmonary fibrosis and control primary mixed lung cultures' (Homo sapiens, score 6, n=28, pdat 2026/10/23 = FRESHEST NOVEL accession of the day, raw_file_availability 'yes', license NCBI public repository [clean +2], query 'lung fibrosis single-cell') is the FIRST NOVEL IPF temporal-primary-culture transcriptomic dataset to surface in the prior id:131-id:135 retention window ## 📋 Synthesis The 2026-10-25 06:00 KST research-watcher scan ran via `bash run.sh scan` per brown-biotech-cron-silent-failure-diagnostics section 20 fixed-instruction: 114 fresh hits across the standard 27-query coverage landed in research-watcher/output/2026-10-25/scan/ (scan.md + scan.json + hits.jsonl all present, 0 source errors). The score-9 top band is again 100% RECYCLED at accession level from the prior id:131-id:135 retention window (GSE349377 CRISPRi-biomaterial-adhesion, GSE328275 TNBC-CD45-scRNA, GSE328422 lymph-node-spatial, GSE326553 opioid-spatial, GSE346380 CosMx-LUAD, GSE348495 CosMx-CRC, GSE288340 Xenium-anti-BCMA-marrow, GSE311507 HNSCC-states, GSE281462-65 3D-chromatin-GWAS quartet) - 0 score-9 first-NOVEL harvest, matching the recycled-top-ladder situation of id:130 through id:135. Per the section 20 recycled-top-ladder-fallback pattern, the actionable NOVEL harvest today comes from a TRI-FILTER through accession-NOT-in-id:131-id:135-retention-window + bb-domain-keyword-positive (TRIM24 + bi-functional degrader + AR/mTOR + residual disease + CRPC + lineage plasticity + STAT3 + EMT cytokines + P-selectin + senescence + senolytic/senomorphic + SMNP nanotherapy + immune exclusion + IPF + idiopathic pulmonary fibrosis + patient-derived primary lung culture + temporal transcriptome) + pdat-recent + mammalian-taxon-preferred: 3 NOVEL signals across 3 distinct BB lanes (AI-DD / Refractory-Cancer Lane, Longevity & Senolytics Lane + Fibrosis Lane, Bioinformatics & Multi-Omics Lane + IPF Lane). All 3 picks are accession-level NOVEL vs id:135 (yesterday's 9p24.1 JAK-blockade lymphoma + MIC13 cristae multi-omics + vervet primate muscle decline triad) - zero overlap, so the NOVELTY GATE is met at 3/3 rather than the required 2/2, and lane diversity is 3/3. Each accession was verified against its NCBI GEO esummary record (title, depositor abstract, taxon, pdat, sample count, supplementary-file availability) rather than title-matching alone; GSE267345 and GSE319260 were additionally cross-read for their full abstracts, and GSE319260 carries PMID 42784692. Runner-up for the Biotech Infrastructure lane is GSE347270 (Swap-seq: pooled twin prime editing + flow-sorting tiling deletion screen mapping enhancers, silencers and topological elements; n=924, Homo sapiens, pdat 2026/10/10), which should be folded into the AI-DD target-inference lane's next pass as a method reference. --- ## 🎯 Highlights ### 1. Signal 1 (AI Drug Discovery Lane + Refractory-Cancer Lane + AR-Inhibition Resistance + TRIM24 Bi-Functional Degrader + Residual-Disease Adaptation + First NOVEL TRIM24-Degrader SuperSeries of the Day) - GSE267347 (SuperSeries, n=125) / GSE267345 (RNA-seq arm, n=21) / GSE267346 (scRNA-seq arm, n=17) 'TRIM24 degradation counteracts adaptation to androgen receptor inhibition in prostate cancer' (Homo sapiens, score 6, pdat 2026/10/23 = FRESHEST NOVEL accession of the day, raw_file_availability 'yes', license NCBI public repository [clean +2], query 'tumor metabolism single-cell'). KEY mechanistic content, read from the depositor abstract: androgen receptor (AR) signaling is the key lineage-specific oncogenic pathway and primary therapeutic target in prostate cancer, but responses to androgen deprivation therapy (ADT) and AR signaling inhibitors (ARSi) are highly variable and progression to fatal castration-resistant prostate cancer (CRPC) is, in many cases, inevitable - driven by AR reactivation, epithelial-to-mesenchymal transition (EMT), and lineage plasticity. Critically, LITTLE IS KNOWN ABOUT THE EARLY ADAPTATION MECHANISMS IN RESIDUAL DISEASE THAT INITIATE THESE PROCESSES. The authors identify TRIM24 as a critical regulator supporting survival of residual cancer-cell subpopulations primed for relapse IN VIVO, and show that degradation of TRIM24 through BI-FUNCTIONAL DEGRADERS (dTRIM24) significantly DELAYS OR ABROGATES the emergence of CRPC driven by AR reactivation and lineage plasticity. Mechanistically dTRIM24 inhibits AR/mTOR signaling in residual disease AND counteracts adaptive pathways directly engaged by AR inhibition, such as STAT3 signaling and the release of EMT-promoting cytokines; its activity extends to CRPC models with limited therapeutic options. The dataset includes ChIP-seq arms for TRIM24, STAT3, AR and H3K27ac in patient-derived xenograft and cell-line models. Why it matters for BB: this is the single most decision-ready refractory-cancer signal in days, because the reasoning layer does not sell the reader 'TRIM24 is a druggable target' (a database row) - it sells the structural insight that in refractory prostate cancer the DECISION-RELEVANT UNIT IS THE RESIDUAL-DISEASE STATE, not the primary driver, and that a target is only worth a degrader if it sustains the residual subpopulation that seeds the relapse. That reframes Brown Biotech's refractory-cancer lane from 'find a new target' to 'identify and deplete the relapse-primed residual population', which is exactly the clinical question clients actually ask. Two concrete payoffs for the AI-DD target-inference stack: (a) bi-functional (PROTAC-style) degradation is a modality the stack does not yet reason about at all - today it gets a citable, in-vivo-validated case where degradation beats inhibition because the target's role is survival-of-residual-disease rather than proliferation; (b) the STAT3 + EMT-cytokine arm shows that the escape mechanism runs through a signalling axis parallel to the drug's own target, which is a generalizable feature for scoring adaptive-resistance hypotheses in the multiomics service line. Caveat for honesty: the arm structure is heterogeneous (cell lines + PDX + patient CR/HS samples) and n is small per arm, so treat it as a mechanism-and-method reference requiring the standard QC notebook, not as an efficacy claim. ### 2. Signal 2 (Longevity & Senolytics Lane + Fibrosis Lane + P-Selectin as a Conserved Senescent-Cell Surface Marker + Senescence-Modulating Nanoparticles (SMNPs) + Reversal of Established Fibrosis + Immune-Exclusion Overcome + First NOVEL P-Selectin-Targeted Senolytic Nanotherapy Dataset of the Day) - GSE319260 'Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer [lung]' (Mus musculus, score 4, n=4, PMID 42784692, pdat 2026/10/14, raw_file_availability 'yes', license NCBI public repository [clean +2], query 'fibrosis perturb-seq'). KEY mechanistic content, read from the depositor abstract and cross-read against the linked PubMed record (PMID 42784692): cellular senescence is a stress-induced program marked by durable cell-cycle arrest plus transcriptional and secretory changes that orchestrate tissue microenvironments. Although TRANSIENT SENESCENCE SUPPORTS TISSUE REPAIR, its CHRONIC PERSISTENCE drives fibrosis, immune suppression and tumor progression. The authors identify P-SELECTIN as a CONSERVED SURFACE MARKER of cells with senescent characteristics accumulating in murine AND human fibrotic tissues and in the immunosuppressive tumor microenvironment of liver and lung cancers. Within this population, MACROPHAGES exhibit canonical senescence features coupled to programs promoting extracellular-matrix deposition and immune evasion. To selectively target the population they engineered P-SELECTIN-TARGETED SENESCENCE-MODULATING NANOPARTICLES (SMNPs) delivering senolytic or senomorphic agents. In preclinical fibrosis models, SMNPs eliminated or reprogrammed pathogenic cells, REVERSED ESTABLISHED FIBROSIS (not merely prevented its onset), and reduced free-drug-associated systemic toxicity. In cancer models, SMNPs remodeled the fibrotic microenvironment and markedly enhanced responses to immune checkpoint-based therapies. Why it matters for BB: this is the highest-value Longevity & Senolytics signal in days and it lands simultaneously in the fibrosis lane, which is Brown Biotech's named anti-fibrotic case-study territory. Three payoffs: (a) it upgrades the senolytics positioning from 'a drug class that removes senescent cells' to 'a SURFACE-MARKER-DIRECTED DELIVERY PLATFORM (P-selectin + nanoparticle) that removes the pathogenic subset while sparing the reparative one' - which is the honest, differentiating version of the senolytics story, because transient senescence is beneficial and only chronic persistence is pathogenic; (b) 'reversed established fibrosis' is a much stronger client-facing claim than 'reduced fibrosis markers', and it is supported by a preclinical mouse model rather than by marker surrogates; (c) the platform generalizes - P-selectin is a conserved marker across murine and human fibrotic tissue AND liver/lung tumor microenvironment, so one delivery vehicle spans the anti-fibrotic service line, the longevity service line, and the refractory-cancer lane (fibrotic immune exclusion). Caveat for honesty: n=4 in GEO and mouse models - this is a preclinical, mechanism-and-platform dataset, not clinical evidence; and it belongs to the senescence program Brown Biotech already tracks (D+Q, pioglitazone), so the value is the DELIVERY/MARKER layer, which is genuinely new relative to the existing senolytic portfolio. ### 3. Signal 3 (Bioinformatics & Multi-Omics Lane + IPF Lane + Idiopathic Pulmonary Fibrosis + Patient-Derived Primary Mixed Lung Cultures + Temporal Transcriptomic Profiling + Culture-Artifact Control + First NOVEL IPF Temporal-Culture Transcriptome of the Day) - GSE351932 'Temporal transcriptomic profiling of idiopathic pulmonary fibrosis and control primary mixed lung cultures' (Homo sapiens, score 6, n=28, pdat 2026/10/23 = FRESHEST NOVEL accession of the day, raw_file_availability 'yes', license NCBI public repository [clean +2], query 'lung fibrosis single-cell'). KEY content, read from the depositor abstract: bulk RNA sequencing was performed to characterize TEMPORAL CHANGES IN GENE EXPRESSION in primary mixed lung cell cultures derived from patients with idiopathic pulmonary fibrosis (IPF) and control donors. Freshly isolated cells AND samples collected during culture were profiled, so that disease-associated differences could be separated from CULTURE-DEPENDENT CHANGES in the transcriptional profiles - i.e. the design explicitly deconvolves the biology from the culture artifact. Why it matters for BB: this is the most directly on-axis dataset in today's scan for the BB fibrosis lane, because IPF is the anchor indication of the anti-fibrotic service line and Brown Biotech's clients repeatedly ask the question this dataset is designed to answer: what does the fibrotic SIGNAL look like in human tissue-derived cells, versus what is an artifact of how we culture them? The design gives the multi-omics reasoning layer a rare NEGATIVE-CONTROL-AXIS dataset (disease x time x fresh-vs-cultured), which is the correct shape for a service that promises decision-ready biomarker shortlisting rather than a DEG list - a candidate that only separates in fresh cells is a culture artifact, and a candidate that separates at time zero is a disease-intrinsic state. Two further payoffs: (a) patient-derived primary mixed lung cultures are a human, non-animal assay system that maps directly onto the human-model argument the Brown Biotech fibrosis service already makes in Paid Briefs; (b) because the profile is TEMPORAL, the dataset can serve as a training/validation reference for the reasoning layer's temporal-degradation module, which is otherwise a hard sell because public fibrosis data is overwhelmingly endpoint-only. Caveat for honesty: bulk RNA-seq on mixed cultures means the cell-type attribution is inferential (no single-cell resolution in this accession), and n=28 is small - treat it as a QC-grade reference and control set for the IPF lane, not as a standalone mechanistic claim. ### 4. Cross-signal synthesis (the NEW observation of the day) - the three NOVEL signals are about TARGETING A STATE THROUGH ITS CARRIER, not about the state itself. Signal 1: do not treat TRIM24 as a housekeeping chromatin factor, degrade it in the RESIDUAL-DISEASE SUBPOPULATION that seeds relapse, so the adaptive escape (AR reactivation + STAT3 + EMT cytokines) never gets installed; and prefer a modality (bi-functional degrader) that removes the protein rather than merely inhibiting its function. Signal 2: do not clear all senescent cells, CLEAR THE PATHOGENIC SUBSET via a conserved surface marker (P-selectin) delivered by a nanoparticle, so the reparative transient-senescence program survives and established fibrosis can actually be reversed. Signal 3: do not read a disease signal out of a culture, SEPARATE DISEASE FROM TIME AND FROM CULTURE, and only trust candidates that separate at the human-tissue-derived, time-zero, fresh-cell layer. Read together they say: THE PRODUCTIVE INTERVENTION IS SELECTED BY HOW THE PATHOLOGIC STATE IS CARRIED AND DELIVERED - which carrier (a residual tumor cell carrying relapse potential, a macrophage carrying a senescent ECM-depositing program, a culture artifact carrying a false signal), and by what vehicle reaches it (a degrader, a targeted nanoparticle, a time-resolved assay). This composes with id:135's amplifying-layer thesis (a chromosomal amplicon as the amplifying layer) and id:134's surface-and-contact thesis (checkpoint surface abundance as the control point) into a three-digest arc whose shared proposition is: THE REASONING LAYER PICKS THE CARRIER AND THE VEHICLE, NOT THE MOLECULE. Brown Biotech implication: 'carrier-and-vehicle intervention selection' is now a three-digest-strength pattern and should be promoted from a per-brief reasoning move to a named published capability note (for example a Brown Biotech 'Carrier & Vehicle' method note) - it is also directly monetizable, because 'which of my two candidates actually reaches the pathogenic cell, and in what form' is a question the database layer can never answer and the Brown Biotech SoI positioning exists to answer. The Biotech Infrastructure lane's supporting asset today is GSE347270 (Swap-seq: pooled twin prime editing + flow-sorting tiling deletion screens; n=924) - a published, open method for dissecting regulatory-element function at scale, which the AI-DD target-inference lane can use as a validated reference instead of inventing its own causal-element scoring. --- ## 💼 Next Steps - **[Open GSE267347 in GEO (TRIM24 degradation vs AR-inhibition adaptation, SuperSeries, n=125)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267347)** - **[Open GSE267345 in GEO (TRIM24 degrader RNA-seq arm, n=21)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267345)** - **[Read TRIM24 degradation / CRPC adaptation paper (PubMed search)](https://pubmed.ncbi.nlm.nih.gov/?term=TRIM24+degradation+adaptation+androgen+receptor+inhibition+prostate+cancer)** - **[Open GSE319260 in GEO (P-selectin senescence-directed nanotherapy, lung fibrosis + immune exclusion)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319260)** - **[Read P-selectin SMNP senolytic nanotherapy paper (PMID 42784692)](https://pubmed.ncbi.nlm.nih.gov/42784692/)** - **[Open GSE351932 in GEO (IPF temporal transcriptomic profiling, patient-derived primary lung cultures, n=28)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE351932)** - **[Read IPF temporal primary-culture transcriptome record (PubMed search)](https://pubmed.ncbi.nlm.nih.gov/?term=temporal+transcriptomic+profiling+idiopathic+pulmonary+fibrosis+primary+lung+cultures)** - **[Open GSE347270 in GEO (Swap-seq prime-editing regulatory-element screen - infrastructure runner-up)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE347270)** - **[Request a carrier-and-vehicle intervention-selection brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[View refractory-cancer service](https://brownbio.tech/services/refractory-cancer)** - **[View AI-DD service](https://brownbio.tech/services/ai-drug-discovery)** - **[View fibrosis service](https://brownbio.tech/services/fibrosis)** - **[View longevity service](https://brownbio.tech/services/longevity)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** - **[View senolytics / longevity service page](https://brownbio.tech/services/longevity#senolytics)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-10-25 06:08 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-10-25
PubMed/GEO scan · research-watcher · 06:00 KST